Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved entities : Ultragenyx pharmaceutical inc. save search
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy
Published: 2021-09-09 (Crawled : 08:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -0.58%
H: 2.56%
C: -0.46%
media treatment approval
MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults
Published: 2021-09-07 (Crawled : 12:15) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 1.8%
H: 1.99%
C: -0.35%
canada approval media treatment injection approval
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and ChildrenDojolvi is the only approved therapy for this rare, life-threatening metabolic disorder
Published: 2021-08-23 (Crawled : 13:00) - biospace.com/
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 4.68%
H: 4.22%
C: 4.04%
treatment brazil therapy metabolic children approval rare
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
Published: 2021-08-23 (Crawled : 13:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 4.68%
H: 4.22%
C: 4.04%
treatment brazil children approval
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain
Published: 2021-07-13 (Crawled : 08:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -0.16%
H: 2.26%
C: -4.01%
media treatment approval
GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome
Published: 2021-06-10 (Crawled : 13:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.2%
H: 8.89%
C: 5.07%
treatment approval syndros
Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
Published: 2021-02-17 (Crawled : 14:01) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -0.67%
H: 1.05%
C: -0.19%
treatment approval children
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.